logo-loader
Silence Therapeutics PLC

Silence Therapeutics CEO talks recent RNAi deals and updates on critical SLN124 trial

Silence Therapeutics PLC's (LON:SLN) David Solomon discusses with Proactive London's Andrew Scott the recent deal between Novartis and The Medicines Company for its asset - the RNAi project inclisiran.

Solomon also updates on their lead candidate, SLN124, which is being developed to treat iron overload disorders.

Quick facts: Silence Therapeutics PLC

Price: 540 GBX

Market: AIM
Market Cap: £423.2 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Silence Therapeutics 'charging ahead with its key...

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates on developments across their three key programmes - SLN 500, 124 and 360. Discussing the firm's current valuation, Solomon says ''there's a lot more steam in the engine''. ''I think that's what's exciting - we're...

on 28/10/19

2 min read